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We determined the occurrence of acquired metallo-β-
lactamase (MBL)–producing bacteria in Korean hospitals.
Among the isolates nonsusceptible to imipenem that were
collected from 28 hospitals from 2000 to 2001, 44 (11.4%)
of 387 Pseudomonas spp. and 38 (14.2%) of 267
Acinetobacter spp. produced MBL and had alleles of
blaVIM-2 or blaIMP-1. MBL-producing isolates were detected
in 60.7% of the hospitals.
Carbapenems are often used as a last resort for treatingserious infections attributable to multidrug-resistant
gram-negative bacilli because these drugs are stable even
to extended-spectrum and AmpC β-lactamases. However,
gram-negative bacilli with acquired metallo-β-lactamase
(MBL), IMP-1, emerged and spread during the early 1990s
in Japan (1). IMP-1 and its variants were then detected in
other countries (2).
Another type of acquired MBL, VIM-1, was first
reported in Pseudomonas aeruginosa in Italy (3), followed
by reports of VIM-2 in France and Greece. VIM-2 was
detected in P. aeruginosa in a Korean hospital isolated as
early as 1995 (4). The occurrence of the VIM enzyme has
continued to evolve: VIM-3 was reported in Taiwan (5),
and VIM-4 in the United States (6).
The blaIMP and blaVIM genes are horizontally transfer-
able because they are inserted in integrons, and some of
these integrons are located on conjugative plasmids (7).
Because of its ability to spread, carbapenem resistance
related to IMP and VIM β-lactamase production has
become a serious concern (8). Laboratory personnel and
physicians must consider the therapeutic and infection-
control implications of not detecting carbapenemase-pro-
ducing bacteria (9). A large number of VIM-2–producing
Pseudomonas spp. have been detected in a Korean hospi-
tal since 1995 (4), but the occurrence of MBL-producing
isolates has not been studied at other Korean hospitals,
despite the high prevalence of carbapenem-resistant P.
aeruginosa and Acinetobacter spp. (10). The aim of our
study was to determine the occurrence of acquired MBL-
producing P. aeruginosa and Acinetobacter spp. among
isolates collected by Korean Nationwide Surveillance of
Antimicrobial Resistance Group hospitals. The MBL types
produced and the sources of the MBL-positive isolates
were also investigated. In addition, pulsed-field gel elec-
trophoresis (PFGE) patterns were compared to determine
intra- and inter-hospital spread of resistant strains.
The Study
Nonduplicate, imipenem-resistant isolates of 387
Pseudomonas spp. and 267 Acinetobacter spp. were col-
lected from 2000 to 2001 from 28 hospitals in the Korean
Nationwide Surveillance of Antimicrobial Resistance
Group hospitals located in six cities or provinces. The
identification of the species and the imipenem susceptibil-
ity were confirmed at the coordinating laboratory by using
conventional tests (11) or ATB 32 GN system (bioMerieux,
Marcy-l’Etoile, France) and by using the disk diffusion
test (12), respectively.
MBL production was screened by using the Hodge test
and the imipenem-EDTA double disk synergy test (13).
The blaIMP-1 and blaVIM-2 alleles were detected by poly-
merase chain reaction (PCR), and three of the positive iso-
lates were confirmed by sequencing, as described previ-
ously (4). XbaI-digested genomic DNA of P. aeruginosa
isolates was separated by PFGE using the CHEF-DR-II
system (Bio-Rad Laboratories, Hercules, CA) (4). The pat-
tern was analyzed visually and by using UVIBand and
Map software (UVItec Ltd., Cambridge, UK).
Some of the Pseudomonas and Acinetobacter isolates
collected were not fully resistant to imipenem but showed
intermediate resistance when retested. Among the isolates
not susceptible to imipenem, 44 (11.4%) of 387
Pseudomonas spp. (42 P. aeruginosa and 2 P. putida) and
38 (14.2%) of 267 Acinetobacter spp. were considered
MBL producers on the basis of positive results by the
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Hodge test and imipenem-EDTA double disk synergy test
(Table 1). MBL-producing Pseudomonas spp. and
Acinetobacter spp. were detected in 11 (52.4%) of 21 and
10 (41.7%) of 24 hospitals that were located in four of five
and five of six cities or provinces, respectively. We detect-
ed the blaVIM allele by PCR from all 42 isolates of MBL-
producing P. aeruginosa and 2 isolates of P. putida. The
blaVIM-2 and blaIMP-1 alleles were detected in 27 (71.1%)
and 11 (28.9%) of 38 Acinetobacter isolates, respectively
(Table 2). Nucleotide sequencing for three representative
PCR-positive isolates confirmed the presence of the
blaVIM-2 gene in one isolate each of P. aeruginosa and
Acinetobacter spp., and the blaIMP-1 gene in one isolate of
Acinetobacter spp. 
The MBL-producing strains were isolated mainly from
intensive-care unit patients (31.7%) and other inpatients
(50.0%); five (6.1%) were from emergency service and
other outpatients (Table 3). Overall, MBL-producing iso-
lates were mainly obtained from specimens of sputum
(50.0%) and urine (29.3%). However, the proportion of
MBL-producing isolates was relatively higher among
urine isolates: 17.3% for Pseudomonas spp. and 29.2% for
Acinetobacter spp. We obtained one MBL-producing
Acinetobacter isolate from each of the following specimen
types: blood, spinal fluid, pleural fluid, and venous
catheter tip (Table 4).
The PFGE of the XbaI-digested genomic DNA of 39
isolates of P. aeruginosa showed 22 patterns (data not
shown). Six isolates from one hospital had an identical pat-
tern. Thirteen isolates (33.3%) belonged to another identi-
cal pattern—six from one hospital, two from each of two
hospitals, and one from each of three hospitals, which were
located in a city and two provinces.
Conclusions
In this study, >10% of all imipenem-nonsusceptible iso-
lates of Pseudomonas spp. and Acinetobacter spp. were
attributable to MBL production (Table 1), and these MBL-
producing isolates were detected in 62.5% of the partici-
pating hospitals. Our finding indicates that MBL-produc-
ing P. aeruginosa is more prevalent in Korea than in other
countries (2) and that MBL-producing Acinetobacter spp.
is increasing. The percentage of hospitals with MBL-pro-
ducing isolates might have been higher if a larger number
of imipenem-nonsusceptible isolates had been collected
for this study. 
VIM-2 was the only type of acquired MBL identified
initially in Korea. VIM-2–producing P. aeruginosa was
isolated at almost the same time in Europe (7) and Korea
(4). However, IMP-1–producing isolates were rare until
2000 in Korea. Only one and three IMP-1-positive P.
aeruginosa and Acinetobacter spp., respectively, have
been isolated at the coordinating laboratory (4, unpub.
data). In our study, 11 (28.9%) of 38 MBL-positive isolates
of Acinetobacter spp. were IMP producers (Table 2). This
increase suggests the possible introduction of IMP-produc-
ing strains of Acinetobacter spp. from Japan, where 28 iso-
lates of blaIMP-1-positive Acinetobacter baumannii were
reported in a hospital as early as 1994 to 1996 (14).
Rasmussen and Bush (15) predicted that an increase of
MBL-producing organisms was inevitable, given the more
frequent use of carbapenems. Imipenem has been used for
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Table 1. Detection of metallo-β-lactamase–producing isolates among imipenem-nonsusceptible isolates of Pseudomonas spp. and 
Acinetobacter spp. 
No. hospitals (%) No. isolates (%) 
Organism City/province Tested Positive Tested Positive 
Seoul 11a 4 (36.4) 144 12 (8.3) 
Kyungki 2 2 (100) 40 6 (15.0) 
Kangwon 2 1 (50.0) 57 2 (3.5) 
Chulla 4 4 (100) 108 24 (22.2) 
Kyungsang 2 0 (0) 38 0 (0) 
Pseudomonas spp. 
Total 21 11 (52.4) 387 44 (11.4) 
Seoul 11a 4 (36.4) 107 12 (11.2) 
Kyungki 3 0 (0) 29 0 (0) 
Kangwon 3 2 (25.0) 41 8 (19.5) 
Chulla 3 1 (12.5) 25 13 (52.0) 
Kyungsang 2 1 (50.0) 53 1 (1.9) 
Chungchung 2 2 (100) 12 4 (33.3) 
Acinetobacter spp. 
Total 24 10 (41.7) 267 38 (14.2) 
aFour were tertiary-care hospitals. 
Table 2. Detection of blaVIM-2 and blaIMP-1 allele from metallo-β-
lactamase–producing Pseudomonas spp. and Acinetobacter  
spp. by polymerase chain reaction 
No. isolates (%) 
Organism Tested 
blaVIM-2  
positive 
blaIMP-1 
positive 
Pseudomonas aeruginosa 42 42 (100) 0 (0) 
P. putida 2 2 (100) 0 (0) 
Acinetobacter spp. 38 27 (71.1) 11 (28.9) 
Total 82 71 (86.6) 11 (13.4) 
only 9 years in Korea, but the imipenem-resistance rate of
P. aeruginosa has rapidly risen from 6% in 1996 to 19% in
2001. A study by the Korean Nationwide Surveillance of
Antimicrobial Resistance Group showed that the mean
imipenem-resistance rates of P. aeruginosa in 1997 did not
differ substantially depending on hospital size, (i.e., 17%
in medium hospitals [<1,000 beds] and 18% in large hos-
pitals [>1,000 beds]). The mean resistance rates to imipen-
em were not lower than those to ceftazidime in 2000, i.e.,
21% versus 18% in large hospitals and 20% versus 19% in
medium hospitals (data not shown).
Acinetobacter spp. are also common nosocomial
pathogens with multidrug resistance. The imipenem resist-
ance rate of this organism isolated in Korea was found to
be much lower than that of P. aeruginosa, but its resistance
rate rose from 4% in the first quarter to 20% in the third
quarter of 2002 at the coordinating laboratory (data not
shown). 
In our study, MBL-producing Pseudomonas spp. and
Acinetobacter spp. were isolated mainly from sputum and
urine specimens, and most (81.7%) isolates were from
inpatients and intensive-care unit patients. Therefore,
proper treatment of respiratory secretions and urine from
intensive-care unit patients is considered an important
aspect of preventing the spread of MBL-producing organ-
isms. The presence of P. aeruginosa isolates with identical
PFGE patterns among those collected not only from cer-
tain hospitals but also from different hospitals suggests
that clonal spread is at least a part of the cause of intra- and
inter-hospital dissemination of MBL-producing isolates.
The presence of VIM-2-producing Serratia marcescens,
Enterobacter cloacae, and Achromobacter xylosoxidans
subsp. denitrificans (unpub. data) in other hospitals also
suggests horizontal transfer of the resistance determinants. 
Cornaglia et al. reported that five of seven patients
infected with MBL-producing P. aeruginosa died,
although the cause of death was difficult to establish with
certainty (16). Clinical studies on the infection are rare
because isolation of MBL-producing gram-negative bacil-
li increased only recently. We anticipate difficulties in
treating patients infected with MBL-producing gram-neg-
ative bacilli, which can hydrolyze, in vitro, all available β-
lactams, except aztreonam for which clinical efficacy is
unknown. 
Our study indicates the urgent need for action to pre-
vent further spread of MBL-producing organisms.
Previous experiences with penicillin-nonsusceptible pneu-
mococci, methicillin-resistant Staphylococcus aureus, van-
comycin-resistant Enterococcus faecium, and extended-
spectrum β-lactamase–producing Klebsiella pneumoniae
indicate that once resistant bacteria can become wide-
spread they cannot be controlled (10). Our first task is to
detect MBL producers among clinical isolates (9).
Although the National Committee for Clinical Laboratory
Standards document (12) does not contain procedures for
detection, simple procedures are available (13).  
The prevalence of blaVIM-2 allele-positive P. aeruginosa
and blaIMP-1 allele-positive Acinetobacter spp. is increasing
possibly because of clonal and horizontal spread of the
resistance determinant in Korean hospitals. Sputum and
urine from inpatients and intensive-care unit patients were
found to be the main sources of MBL-producing isolates.
Laboratories not only in Korea but also in other countries
with carbapenem-resistant organisms must be prepared to
screen MBL-producing isolates to determine the clinical
impact and prevent further spread of MBL-producing
organisms. 
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Table 3. blaVIM-2 and blaIMP-1 allele-positive Pseudomonas spp. and Acinetobacter spp. isolated by service 
No. isolates (%) 
Organism Outpatient Inpatient Intensive-care unit Others Total 
Pseudomonas spp. 3 (6.8)a 26 (59.1) 11 (25.0) 4 (9.1) 44 (100) 
Acinetobacter spp. 2 (5.2)b 15 (39.5) 15 (39.5) 6 (15.8) 38 (100) 
Total 5 (6.1) 41 (50.0) 26 (31.7) 10 (12.2) 82 (100) 
aTwo were emergency service patients, and one was a urology patient. 
bOne was an emergency service patient, and one was a pediatric patient. 
Table 4. blaVIM-2 and blaIMP-1 allele-positive Pseudomonas spp. and Acinetobacter spp. isolated by source 
No. (%) of isolates with metallo-â-lactamase 
Pseudomonas spp. Acinetobacter spp. Total 
Source Tested Positive Tested Positive Tested Positive 
% positive by 
source 
Sputum 200 22 (11.0) 143 19 (13.3) 343 41 (12.0) 50.0 
Urine 98 17 (17.3) 24 7 (29.2) 122 24 (19.7) 29.3 
Wound  49 2 (4.1) 71 7 (9.9) 120 9 (7.5) 10.9 
Othera  18 3 (16.7) 29 5 (17.2) 47 8 (17.0) 9.8 
Total 387 44 (11.4) 267 38 (14.2) 654 82 (12.5) 100 
aOthers included one Acinetobacter isolate of specimens from blood, spinal fluid, pleural fluid, and a venous catheter tip. 
Acknowledgments
We thank Jong Hwa Yum and Dongeun Yong for detecting
the metallo-β-lactamase genes and Yonghee Suh for screening
the MBL producers. 
Dr. Lee is director of the Research Institute of Bacterial
Resistance and a professor in the Department of Laboratory
Medicine, Yonsei University College of Medicine, Seoul, Korea.
He is the Korean coordinator in the World Health
Organization/Centers for Disease Control and Prevention
External Quality Assurance Scheme, and he is the organizer of
the Korean Nationwide Surveillance of Antimicrobial Resistance
Group. His research interests include antimicrobial resistance of
bacteria and its mechanisms. 
References
1. Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horii T, Ito H, et
al. Molecular characterization of an enterobacterial metallo-β-lacta-
mases found in a clinical isolates of Serratia marcescens that shows
imipenem resistance. Antimicrob Agents Chemother 1994;38:71–8.
2. Gibb AP, Tribuddharat C, Moore RA, Louie TJ, Krulicki W,
Livermore DM, et al. Nosocomial outbreak of carbapenem-resistant
Pseudomonas aeruginosa with a new blaIMP allele, blaIMP-7.
Antimicrob Agents Chemother 2002;46:255–8. 
3. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G,
Fontana R, et al. Cloning and characterization of blaVIM, a new inte-
gron-borne metallo-β-lactamase gene from a Pseudomonas aerugi-
nosa clinical isolate. Antimicrob Agents Chemother 1999;
43:1584–90.
4. Lee K, Lim JB, Yum JH, Yong D, Chong Y, Kim JM, et al. blaVIM-2
cassette-containing novel integrons in metallo-β-lactamase–produc-
ing Pseudomonas aeruginosa and Pseudomonas putida isolates dis-
seminated in a Korean hospital. Antimicrob Agents Chemother
2002;46:1053–8.
5. Yan J-J, Hsueh P-R, Ko W-C, Luh E-T, Tsai S-H, Wu H-M, et al.
Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and
identification of VIM-3, a novel variant of the VIM-2 enzyme.
Antimicrob Agents Chemother 2001;45:2224–8. 
6. Tolman MA, Rolston K, Jones RN, Walsh TR. Molecular characteri-
zation of VIM-4, a novel metallo-beta-lactamase isolated from Texas:
report from the cancer surveillance program (2001). Proceedings of
the 42nd Interscience Conference on Antimicrobial Agents and
Chemotherapy. Abstract C1-1851. San Diego, California; 2002. 
7. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo T-D, et al.
Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lac-
tamase and its plasmid- and integron borne gene from a Pseudomonas
aeruginosa clinical isolate in France. Antimicrob Agents Chemother
2000;44:891–7.
8. Richet HM, Mohammed J, McDonald LC, Jarvis WR, INSPEAR.
Building communication networks: International Network for the
Study and Prevention of Emerging Antimicrobial Resistance. Emerg
Infect Dis 2001;7:319–22.
9. Molland ES, Black JA, Ourada J, Reisbid MD, Hanson ND, Thomson
KS. Occurrence of newer β-lactamases in Klebsiella pneumoniae iso-
lates from 24 U.S. hospitals. Antimicrob Agents Chemother
2002;46:3837–42. 
10. Lee K, Lee HS, Jang SJ, Park AJ, Lee MH, Song WK, et al.
Antimicrobial resistance surveillance of bacteria in 1999 in Korea
with a special reference to resistance of enterococci to vancomycin
and gram-negative bacilli to third generation cephalosporin, imipen-
em, and fluoroquinolone. J Korean Med Sci 2001;16:262–70. 
11. Kiska DL, Gilligan PH. Pseudomonas. In: Murray PR, Baron EJ,
Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical
microbiology, 7th ed. Washington: American Society for
Microbiology; 1999. p. 517–25.
12. National Committee for Clinical Laboratory Standards. Performance
standards for antimicrobial susceptibility testing. Eleventh informa-
tional supplement. NCCLS document M100-S11. Wayne (PA): The
Committee, 2001.
13. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified
Hodge test and EDTA-disk synergy tests to screen metallo-β-lacta-
mase-producing strains of Pseudomonas and Acinetobacter species.
Clin Microbiol Infect 2001;7:88–91.
14. Takahashi A, Yomoda S, Kobayashi I, Kubo T, Tsunoda M, Iyobe S.
Detection of carbapenemase-producing Acinetobacter baumannii in a
hospital. J Clin Microbiol 2000;38:526–9.
15. Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases.
Antimicrob Agents Chemother 1997;41:223–32. 
16. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R.
Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa
producing VIM-1, a novel transferable metallo-β-lactamase. Clin
Infect Dis 2000;31:1119–25.
Address for correspondence: Yunsop Chong, Department of Laboratory
Medicine and Research Institute of Bacterial Resistance, Yonsei
University College of Medicine, 134 Shinchon-dong Seodaemun-ku,
Seoul, Korea 120-752; fax: 82-2-313-0908; email: whonetkor@
yumc.yonsei.ac.kr
Emerging Infectious Diseases • Vol. 9, No. 7, July 2003 871
DISPATCHES
